Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity's financial outlook is bolstered by its strategic shift from TST to IGRA, which is projected to contribute several basis points to market growth annually, enhancing the overall revenue trajectory. The company benefits from a robust product portfolio, including a high-growth software solution, a leading life sciences reagents franchise, and a strong immunodiagnostics division, which together increase its profitability potential and streamline operations for future growth. Additionally, Revvity's above-market growth in key segments, coupled with ongoing margin improvements resulting from operational efficiencies, positions the company favorably for sustained financial performance.

Revvity's financial outlook is negatively impacted by a significant decline in its China revenue, particularly in Immunodiagnostics, which saw a drop of DD% in 2Q25, and is expected to fall to less than 5% of total revenue by 2026. Economic conditions, along with industry funding cuts, could slow customer demand, thereby affecting Revvity's growth, market share, and overall performance. Additionally, macroeconomic challenges could create disruptions in the supply chain, potentially leading to product shortages, transit delays, and increased costs, further compromising the company’s operational stability.